Total Payments
$5,038
2024 Payments
$155.37
Companies
36
Transactions
243
Medicare Patients
834
Medicare Billing
$130,321
Payment Breakdown by Category
Food & Beverage$5,029 (99.8%)
Education$9.73 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,029 | 241 | 99.8% |
| Education | $9.73 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $994.14 | 49 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $450.30 | 18 | $0 (2024) |
| Lilly USA, LLC | $399.64 | 24 | $0 (2024) |
| Novo Nordisk Inc | $349.65 | 26 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $305.73 | 6 | $0 (2019) |
| Allergan, Inc. | $274.33 | 4 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $239.11 | 15 | $0 (2024) |
| Amarin Pharma Inc. | $191.91 | 8 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $147.27 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $146.64 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $155.37 | 8 | ABBVIE INC. ($71.68) |
| 2023 | $633.33 | 37 | AbbVie Inc. ($271.91) |
| 2022 | $923.46 | 51 | ABBVIE INC. ($251.40) |
| 2021 | $666.24 | 34 | AbbVie Inc. ($295.12) |
| 2020 | $492.65 | 27 | Novo Nordisk Inc ($121.44) |
| 2019 | $1,897 | 81 | AstraZeneca Pharmaceuticals LP ($276.25) |
| 2017 | $270.68 | 5 | AstraZeneca Pharmaceuticals LP ($127.18) |
All Payment Transactions
243 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/30/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.01 | General |
| Category: Cardiovascular | ||||||
| 07/23/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: PSYCHIATRY | ||||||
| 06/05/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Diabetes | ||||||
| 03/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: NEUROSCIENCE | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Respiratory | ||||||
| 02/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: NEUROSCIENCE | ||||||
| 01/30/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: NEUROSCIENCE | ||||||
| 12/01/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.64 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/23/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.94 | General |
| Category: NEUROSCIENCE | ||||||
| 10/19/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/02/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $29.90 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: RESPIRATORY | ||||||
| 09/11/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: Cardio-renal | ||||||
| 08/09/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/02/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $4.99 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $2.85 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $2.85 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $2.85 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $1.43 | General |
| Category: NEUROSCIENCE | ||||||
| 05/12/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 163 | 307 | $89,857 | $27,576 |
| 2022 | 4 | 182 | 360 | $138,518 | $32,786 |
| 2021 | 5 | 220 | 387 | $134,680 | $37,384 |
| 2020 | 7 | 269 | 442 | $113,579 | $32,575 |
Total Patients
834
Total Services
1,496
Medicare Billing
$130,321
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 198 | $39,600 | $16,715 | 42.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 34 | $9,520 | $4,524 | 47.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $31,947 | $2,911 | 9.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 28 | $3,810 | $1,613 | 42.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,355 | $1,289 | 38.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 12 | 13 | $1,625 | $524.16 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 219 | $44,205 | $19,477 | 44.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 35 | $48,666 | $5,383 | 11.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 54 | $38,888 | $4,298 | 11.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 52 | $6,760 | $3,628 | 53.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 239 | $48,175 | $21,457 | 44.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 50 | 50 | $71,975 | $7,910 | 11.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 44 | 64 | $8,320 | $4,093 | 49.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 23 | 23 | $3,900 | $3,028 | 77.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 11 | 11 | $2,310 | $895.30 | 38.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 70 | 133 | $26,760 | $10,225 | 38.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 71 | 143 | $18,590 | $7,329 | 39.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 32 | 32 | $46,064 | $4,843 | 10.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 33 | 33 | $5,700 | $3,795 | 66.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 30 | 68 | $8,490 | $3,760 | 44.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 22 | 22 | $4,620 | $1,540 | 33.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $3,355 | $1,084 | 32.3% |
About Dr. Asif Bhutto, M.D
Dr. Asif Bhutto, M.D is a Geriatric Medicine healthcare provider based in Bridgeton, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2008. The National Provider Identifier (NPI) number assigned to this provider is 1205093473.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Asif Bhutto, M.D has received a total of $5,038 in payments from pharmaceutical and medical device companies, with $155.37 received in 2024. These payments were reported across 243 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($5,029).
As a Medicare-enrolled provider, Bhutto has provided services to 834 Medicare beneficiaries, totaling 1,496 services with total Medicare billing of $130,321. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Other Specialties Internal Medicine, Geriatric Medicine
- Location Bridgeton, MO
- Active Since 05/16/2008
- Last Updated 03/15/2021
- Taxonomy Code 207RG0300X
- Entity Type Individual
- NPI Number 1205093473
Products in Payments
- VRAYLAR (Drug) $540.22
- UBRELVY (Drug) $310.23
- Ozempic (Drug) $266.75
- REXULTI (Drug) $194.10
- Vascepa (Drug) $191.91
- TRULICITY (Drug) $160.36
- FARXIGA (Drug) $152.86
- ENTRESTO (Drug) $150.43
- HETLIOZ (Drug) $130.72
- LATUDA (Drug) $124.99
- LINZESS (Drug) $124.99
- VIBERZI (Drug) $124.99
- BYDUREON (Drug) $122.18
- MOUNJARO (Drug) $117.54
- Kerendia (Drug) $112.08
- JARDIANCE (Drug) $108.09
- MYRBETRIQ (Drug) $106.43
- XARELTO (Drug) $104.95
- Venclexta (Drug) $104.03
- STEGLATRO (Drug) $98.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.